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Abstract
Background: Human monoclonal antibodies (MAbs) are needed for colon cancer radioimmunotherapy (RIT) to
allow for repeated injections. Carcinoembryonic antigen (CEA) being the reference antigen for immunotargeting
of these tumors, we developed human anti-CEA MAbs.
Methods: XenoMouse®-G2 animals were immunized with CEA. Among all the antibodies produced, two of
them, VG-IgG2κ and VG-IgM, were selected for characterization in vitro in comparison with the human-mouse
chimeric anti-CEA MAb X4 using flow cytometry, surface plasmon resonance, and binding to radiolabeled soluble
CEA and in vivo in human colon carcinoma LS174T bearing nude mice.
Results: Flow cytometry analysis demonstrated binding of MAbs on CEA-expressing cells without any binding on
NCA-expressing human granulocytes. In a competitive binding assay using five reference MAbs, directed against
the five Gold CEA epitopes, VG-IgG2κ and VG-IgM were shown to be directed against the Gold 4 epitope. The
affinities of purified VG-IgG2κ and VG-IgM were determined to be 0.19 ± 0.06 × 108 M-1 and 1.30 ± 0.06 × 108
M-1, respectively, as compared with 0.61 ± 0.05 × 108 M-1 for the reference MAb X4. In a soluble phase assay, the
binding capacities of VG-IgG2κ and VG-IgM to soluble CEA were clearly lower than that of the control chimeric
MAb X4. A human MAb concentration of about 10-7 M was needed to precipitate approximatively 1 ng 125I-rhCEA
as compared with 10-9 M for MAb X4, suggesting a preferential binding of the human MAbs to solid phase CEA.
In vivo, 24 h post-injection, 125I-VG-IgG2κ demonstrated a high tumor uptake (25.4 ± 7.3%ID/g), close to that of
131I-X4 (21.7 ± 7.2%ID/g). At 72 h post-injection, 125I-VG-IgG2κ was still concentrated in the tumor (28.4 ±
11.0%ID/g) whereas the tumor concentration of 131I-X4 was significantly reduced (12.5 ± 4.8%ID/g). At no time
after injection was there any accumulation of the radiolabeled MAbs in normal tissues. A pertinent analysis of VG-
IgM biodistribution was not possible in this mouse model in which IgM displays a very short half-life due to poly-
Ig receptor expression in the liver.
Conclusion: Our human anti-CEA IgG2κ is a promising candidate for radioimmunotherapy in intact form, as
F(ab')2 fragments, or as a bispecific antibody.
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Background
During the last few years, radioimmunotherapy (RIT)
using MAbs to specifically target therapeutic radiation
doses to tumors has led to objective responses in radio-
sensitive hematological cancers, particularly, in non-
Hodgkin's lymphoma (NHL) [1,2]. On the basis of these
clinical results, ibritumomab tiuxetan (90Y-Zevalin; IDEC
Pharmaceuticals) was registered for treatment of relapsed,
indolent, and transformed CD20+  NHL and, more
recently, tositumomab (131I-Bexxar; Corixa) received reg-
ulatory approval; development of other promising prod-
ucts is in the pipeline [3].
Although targeting of solid tumors with radiolabeled anti-
bodies was first reported years ago [4,5], RIT success in
such tumors has been limited to patients with stable dis-
ease, occasional mixed responses, and serological
responses [6-8]. Different parameters can be considered as
responsible for these results: (i) the decreased radiosensi-
tivity of solid tumors as compared with hematological
cancers [9,10], (ii) the difficult penetration of MAbs in
solid tumors [11], and (iii) consequently, the limited radi-
ation dose that can be delivered to the tumor [12,13].
However, recent studies have reported a therapeutic win-
dow for RIT in solid tumors in small-volume and minimal
residual disease [8] and in combination with chemother-
apy [14]. The authors of all the recent pertinent clinical
studies agree with the need of repeated injections for RIT
of solid tumors and, consequently, with the need of
humanized or, preferentially, human MAbs [14,15].
Colorectal cancers represent a high percentage of solid
tumors and are dramatically in need of therapeutic
progress. Surgery is the only potentially curative treat-
ment. Despite recent developments in chemotherapy pro-
tocols, the overall median survival in metastatic colorectal
cancer remains inferior to two years, and the recurrence
rate after resection of a stage III tumor is up to 50% [16-
18]. For RIT of colorectal cancers, carcinoembryonic anti-
gen (CEA) is a preferential target antigen since (i) it is
expressed in almost all tumors (>95%), (ii) it is available
at high antigenic density on the cell surface, and (iii)
many clinical studies have demonstrated a low MAb
uptake in normal intestine despite CEA expression on
these tissues. The only limitation of CEA as target antigen
in RIT is the possible presence of circulating CEA in the
serum of cancer patients, but this is without consequence
in small-volume and minimal residual disease in which
its level is generally low [19].
Different chimeric or humanized anti-CEA MAbs have
been described and evaluated in experimental and clinical
studies [8,14,15,19,20]. In the present study using the
XenoMouse® technology, we describe the generation and
the characterization of two fully human anti-CEA anti-
bodies, one IgG2κ and one IgM, designed for RIT of color-
ectal cancers.
Methods
Generation of fully human MAbs from XenoMouse® strains
Generation and characterization of the XenoMouse®-G2
strain, engineered to produce fully Human IgG2κ anti-
bodies, was described by Mendez et al. [21]. XenoMouse®-
G2 animals were immunized i.p. with 20 µg of human
recombinant CEA (rhCEA) [22] emulsified in complete
Freund's adjuvant for the primary immunization and in
incomplete Freund's adjuvant for additional immuniza-
tions carried out at one month intervals. Immunization
was repeated three to five times. Two days before fusion,
mice were boosted i.v. with 100 µg rhCEA in phosphate
buffered saline (PBS). Spleen cells from immunized mice
were fused with the non-secretory myeloma P3-X63-
Ag.8.653 by addition of polyethylene glycol (PEG) and
were subjected to HAT selection. Wells containing grow-
ing cells were evaluated for the production of the desired
antibody, and if positive, the cultures were cloned. The
hybridomas described in this report were subcloned at
least five times.
Reference anti-CEA MAbs and control MAb
The mouse-human chimeric MAb X4 was used as positive
control in all the experiments. MAb X4 was constructed
using the variable domains from the murine MAb CE25
and the constant domains from a human IgG4κ subclass
[23,24]. It is specific for the CEA epitope Gold 4 [24] and
does not cross-react with NCA or other granulocyte pro-
teins [25]. Chimeric MAb X4 was produced in Sp2/0 cells
transfected with a single vector containing both the chi-
meric heavy and light chains [24]. Murine MAbs F6, 35A7,
B17, CE25, and 192, which are specific for the CEA
epitopes Gold 1 to 5, respectively, were used for epitope
determination [26]. MAb F6 was kindly provided in puri-
fied form by Schering-CIS Biointernational (Gif-sur-
Yvette, France). MAbs 35A7, B17, CE25, and 192 were
produced from mouse hybridoma ascites fluid by ammo-
nium sulfate precipitation and ion-exchange chromatog-
raphy. The human IgG MonoD, kindly provided by
MAbgène (Alès, France), was used as irrelevant human
IgG1 [27].
Cell lines and human granulocytes
The CEA-positive human colon carcinoma LS174T cell
line [28] was obtained from the Cell Distribution Center,
American Type Culture Collection (Rockville, MD). The
CO115-5F12 clone, obtained by transfection of the full-
length CEA-cDNA in a CEA negative clone of the CO115
human colon carcinoma cell line, has been described
[29]. Cells were grown in RPMI 1640 medium containing
10% heat-inactivated fetal bovine serum, streptomycin
(0.1 mg/ml), penicillin (0.1 IU/ml), and amphotericin BBMC Cancer 2004, 4:75 http://www.biomedcentral.com/1471-2407/4/75
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(0.25 µg/ml). The neomycin analogue G418 was added at
a concentration of 200 µg/ml to the CO115-5F12 cell cul-
ture. All culture medium supplements were purchased
from Life Technologies, Inc. (Gibco BRL, Gaithersburg,
MD). For flow cytometry analysis, cells were harvested
after incubation for a few minutes in trypsin-EDTA (0.5
mg/ml and 0.2 mg/ml, respectively).
Granulocytes were obtained from heparin-treated human
peripheral blood by using gradient density centrifugation
methods. A double gradient was formed by layering an
equal volume of HISTOPAQUE®-1077 and HISTO-
PAQUE®-1119. Following centrifugation at 700 g for 30
minutes, cells of the granulocytic series were found at the
1077/1119 interphase.
Screening by ELISA and flow cytometry
The specificity of the antibodies in hybridoma superna-
tants was determined by ELISA using rhCEA to capture the
antibodies (coating overnight at 2 µg/ml rhCEA at room
temperature). Horse radish peroxidase (HRP)-conjugated
goat anti-human IgGκ (Sigma, Lyon, France) and HRP-
conjugated sheep anti-human IgG (γ chain) (Silenius,
Hawthorn, Australia) were used as detection antibodies.
Determination of CEA or NCA specific antibodies in
hybridoma supernatants was carried out by flow cytome-
try using CEA positive cells (CO115-5F12) and NCA pos-
itive cells (human granulocytes). About 5 × 105 cells were
incubated for 1.5 h at 4°C with hybridoma supernatants
or controls (RPMI medium for background measurement
and RPMI containing 20 µg/ml MAb X4 for positive con-
trol). After washing, the cells were incubated with an FITC
conjugated goat anti-human IgG kappa light chain
(Sigma) or with the murine anti-human µ chain DA4-4
(ATCC HB-57), FITC labelled in our laboratory, for 1 h at
4°C; then they were washed twice before analysis on a
FACScanII (Becton-Dickinson, Le-Pont-De-Claix, France).
Each figure represents data obtained from analysis of
10000 cells.
Human MAb production, purification, and molecular 
characterization
The percentage of fetal calf serum was gradually reduced
in the culture medium before MAb purification (10, 5, 2.5
and 0%). MAbs were purified from large volumes of
hybridoma supernatants or ascites produced in nude mice
using Hitrap® NHS-anti-human  κ chain MAb HP6053
(ATCC CRLC-1758).
Proteins separated on SDS-PAGE 6% polyacrylmamide
gels were transferred to a nitrocellulose membrane (Pro-
tran BA85, Schleicher and Schuell, Dassel, Germany).
Non-specific binding sites were blocked overnight at 4°C
by incubation with 5% (w/v) non-fat dry milk in TBS. The
membrane was probed for 2 h at room temperature with
serum diluted 1:1000 or the following antibodies: anti-
human κ light chain-HRP conjugate (A7164, Sigma), anti-
human λ light chain-HRP conjugate (A5175, Sigma), anti-
human µ chain-HRP conjugate (A0420, Sigma), rabbit
anti-human J chain-specific antiserum [30]. Bound serum
antibodies were detected with a goat anti-rabbit whole
molecule-alkaline phosphatase (AP) conjugate (A8025,
Sigma). HRP was detected by addition of a chloronaph-
thol (Sigma) solution containing 0.05% of hydrogen per-
oxide and AP by addition of BCIP-NBT (Sigma). A human
pentameric IgM anti-Rhesus D including a J chain, kindly
provided by MAbgène (Alès, France), was used as positive
control[27].
Antibody VH and Vκ cDNAs were recovered from hybrid-
omas by RT-PCR and sequenced using the ABI-PRISM Big
Dye Terminator Cycle Sequencing Kit (Perkin Elmer, Bos-
ton, MA). Determination of V, D, and J gene usage was
performed using in silico methods.
Measurement of antibody affinity to CEA
The affinities of the antibodies for CEA were determined
by using surface plasmon resonance (SPR) technology
(Biacore AB, Uppsala, Sweden). rhCEA [22] was immobi-
lized on a CM5 sensor chip by the method of thiol liga-
tion according to the manufacturer's instructions
(BIACORE Methods Manual Supplement 5a). Each MAb
was injected at a concentration of 50 µg/ml in HBS buffer
(Hepes-buffered saline, pH 7.4, 3 mM EDTA ; 0.05%
BIACORE surfactant) at a flow rate of 20 µl/min. Dissoci-
ation was carried out in running buffer (HBS). Regenera-
tion of the sensor chip was performed by using 15 µl of
100 mM HCl. The kinetic parameters were determined by
using BIAevaluation 3.2 software.
MAbs and CEA radioiodination
Batches of 50 µg or 100 µg of MAb or rhCEA were labelled
with 4.6 MBq or 11.5 MBq, respectively, of 125I or 131I,
kindly provided by Schering-CIS Biointernational by the
iodogen method (1,3,4,6-tetrachloro-3α, 6α-diphenylgly-
coluryl, Sigma). Free radioiodine was separated from the
protein on a Sephadex G-25 column (Pharmacia) equili-
brated in PBS, pH 7.4.
Binding of MAbs to CEA in a soluble phase assay
About 1 ng 125I-rhCEA (final concentration 16.7 × 10-12
M) was incubated with increasing concentrations of anti-
body (68.3 × 10-12 to 33.3 × 10-15 M) for 2 h in 0.15 M
phosphate buffer, pH 7.4. CEA-antibody complexes were
precipitated at 4°C with 53.5% (v/v) saturated ammo-
nium sulfate. Background binding to an irrelevant human
IgG, MonoD, was subtracted. The radioactivity precipi-
tated with a rabbit polyclonal anti-CEA serum was taken
as 100%.BMC Cancer 2004, 4:75 http://www.biomedcentral.com/1471-2407/4/75
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Epitope mapping by RIA
A competitive binding assay of radiolabeled human MAb
and unlabeled anti-CEA MAb was used to determine the
CEA epitope recognized by the human MAbs. RhCEA
(100 ng/well) in TBS was coated on microtiter wells over-
night at room temperature. An excess (500 ng/well) of
each of the different reference anti-CEA MAbs, specific for
the Gold epitopes 1 to 5, was then added to the wells and
incubated for 1.5 h at 37°C. Then, without washing, each
125I-human MAb (15 ng) was added to the wells and incu-
bated for 1 h 30 at 37°C. The percentage of binding was
determined by measuring the radioactivity bound to the
rhCEA after two washings.
Biodistribution studies
Two million LS174T cells were grafted s.c. into the right
flank of female Swiss nude mice (nu/nu, Iffa Credo,
l'Arbresle, France). When the tumors had reached a vol-
ume of about 150 mm3 (100 to 300 mm3), mice were
grouped according to tumor volume. Lugol iodine solu-
tion (10% solution) was added to the drinking water one
day before the injection of radiolabeled MAbs. Groups of
four mice were injected with a 125I-labeled human MAb
(VG-IgG2κ or VG-IgM) together with 131I-labeled chi-
meric MAb X4 as positive control. The total amount of
each injected antibody was adjusted to 8 µg protein by
adding unlabeled MAb. To determine the biodistribution
of the MAbs, mice were sacrificed 24 or 72 h after injec-
tion. The blood, tumor, and all normal organs were
weighed, and the differential radioactivity was measured
in a dual channel scintillation counter. The results are
expressed as the percentage of the injected dose of radio-
activity present per gram of tissue (% ID/g).
Results
Human anti-CEA MAb characterization
In order to develop human anti-CEA MAbs, XenoMouse®-
G2 animals were immunized with rhCEA. The XenoM-
ouse®-G2 strain produces both fully human IgG2κ and
fully human IgMκ antibodies as part of the normal
immune response, as described by Mendez et al. [21].
Fusion of splenic B cells from immunized mice with
mouse myeloma cells yielded a panel of hybridomas that
secreted human anti-CEA antibodies as determined by
ELISA and flow cytometry analysis (data not shown).
These MAbs were produced for in vivo tumor targeting
purposes. For this reason, (i) hybridoma supernatants
were screened by flow cytometry because, by this tech-
nique, the selection is made on cell membrane-bound
CEA, which is in a conformation as close as possible to
that observed in vivo; and (ii) hybridoma supernatants
were screened on human granulocytes to eliminate all
hybridomas producing anti-NCA antibodies.
Among the 52 antibodies produced, two, VG-IgG2κ and
VG-IgM, were selected for further characterization based
on hybridoma stability and flow cytometry analysis
results. VH and VL domains sequencing confirmed the VG-
IgG2κ and VG-IgM monoclonality and the isotype (data
not shown). Flow cytometry analysis demonstrated strong
binding of purified MAbs on CEA-expressing cells
CO115-5F12 (Figure 1A) without any binding on NCA-
expressing human granulocytes (Figure 1B).
MAb VG-IgG2κ and VG-IgM epitope specificities were
determined in a competitive binding assay using five ref-
erence MAbs directed against the Gold 1 to 5 CEA
epitopes [26]. As demonstrated by this assay (Table 1), the
two human MAbs were directed against the CEA Gold 4
epitope since they were only inhibited by the murine MAb
CE25 and the chimeric MAb X4. A partial inhibition,
attributed to steric hindrance, was observed with MAb
B17 (Gold 3) for VG-IgG2κ (31%) and X4 (13%).
VG-IgM was further analyzed for the presence of J chain
using western blot. The J chain is a ligand for the poly-Ig
receptor expressed on mouse hepatocytes. Figure 2 con-
firms that VG-IgM is constituted of human κ light chain,
human µ heavy chain, and J chain as compared with an
anti-Rhesus D IgM which also contains a J chain but is
composed of a λ light chain [27].
MAb binding to solid phase CEA and to soluble phase CEA
Using surface plasmon resonance technology, the affini-
ties of purified VG-IgG2κ and VG-IgM were determined to
be 0.19 ± 0.06 × 108 M-1 and 1.30 ± 0.06 × 108 M-1, respec-
tively, as compared with 0.61 ± 0.05 × 108 M-1 for the ref-
erence MAb X4.
MAb binding to soluble phase CEA was measured using
trace amounts of 125I-CEA incubated with increasing con-
centrations of antibodies (Figure 3). The binding capaci-
ties of VG-IgG2κ and VG-IgM to soluble CEA were found
to be clearly lower than that of the control chimeric MAb
X4. A human MAb concentration of about 10-7 M was
needed to precipitate around 1 ng 125I-rhCEA (final con-
centration 16.7 × 10-12 M) as compared with 10-9 M for
MAb X4 (Figure 3).
Biodistribution studies
The human MAbs were compared to the chimeric MAb X4
in nude mice bearing human colon carcinoma LS174T
xenografts. Two groups of four mice were co-injected with
125I-VG-IgG2κ and 131I-X4. In the first group of mice dis-
sected 24 h post-injection, 125I-VG-IgG2κ demonstrated a
high tumor uptake (25.4 ± 7.3% ID/g), very close to that
of 131I-X4 (21.7 ± 7.2% ID/g) (Figure 4). At 72 h post-
injection, the 125I-VG-IgG2κ was still concentrated in the
tumor with 28.4 ± 11.0% ID/g whereas the tumorBMC Cancer 2004, 4:75 http://www.biomedcentral.com/1471-2407/4/75
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concentration of 131I-X4 was significantly reduced, with
only 12.5 ± 4.8% ID/g (Figure 4). This difference was
attributed to a higher in vivo stability of VG-IgG2κ than X4
since the %ID recovered in the whole mouse at that time
was 74.1 ± 1.5 and 55.6 ± 1.6 for the human and the chi-
meric MAbs, respectively. At no time after injection was
there any accumulation of the radiolabeled MAbs in nor-
mal tissues. At 24 h, the tumor-to-normal tissue ratios of
the antibodies were in the same range for 131I-X4, with
representatives values of 10.98 ± 0.35, 28.78 ± 0.36, and
2.24 ± 0.38 for liver, muscle and blood, respectively, and
for 125I-VG-IgG2κ, which gave values of 8.63 ± 0.30, 28.30
± 0.31, and 1.74 ± 0.32 for the same organs, respectively
(Table 2). At 72 h, the increase in the tumor-to-normal tis-
sue ratios was very similar for the two MAbs (Table 2).
Flow cytometry analysis Figure 1
Flow cytometry analysis. Flow cytometry analysis of MAbs VG-IgG2κ, VG-IgM, and X4 reactivity against the CEA-express-
ing CO115-5F12 human colon carcinoma cell line (A) and NCA-expressing human granulocytes (B). 12A11 and 16B10 are two 
human anti-CEA MAbs that cross-react with NCA. 192 is a murine anti-CEA MAb that cross-reacts with NCA. Binding of the 
different primary antibodies was detected using either anti-human κ chain, anti-human µ chain, or anti-mouse γ chain as 
indicated.BMC Cancer 2004, 4:75 http://www.biomedcentral.com/1471-2407/4/75
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In two other groups of mice, 125I-VG-IgM was co-injected
with 131I-X4. The reference chimeric MAb X4 gave tumor
localization results comparable to that obtained when it
was co-injected with 125I-VG-IgG2κ (19.1 ± 1.9 and 11.9 ±
3.1% ID/g tumor at 24 h and 72 h, respectively). Due to
the mouse poly-Ig receptor expression in liver, 125I-VG-
IgM was eliminated very rapidly, giving only 3.7 ± 1.0 and
0.3 ± 0.1% ID/g blood at 24 h and 72 h, respectively. This
short clearance was responsible for a low tumor uptake
(7.4 ± 2.8 and 1.8 ± 2.4% ID/g tumor at 24 h and 72 h,
respectively). The percentage of injected MAb recovered in
the whole mouse at 24 h was only 20.5% for 125I-VG-IgM
as compared with 53.7% for 131I-X4.
Discussion
Monoclonal antibodies are now routinely used in the
clinic. Whereas the first generation of MAbs were murine
or chimeric antibodies, it is now clear that the best clinical
results are obtained with humanized or fully human
MAbs [31]. Fully human antibodies such as ABX-EGF are
anticipated to exhibit a long serum half-life and minimal
immunogenicity with repeated administration, even in
immunocompetent patients [32].
In some situations, naked MAbs have demonstrated their
therapeutic efficacy, particularly, when the target antigen
is a receptor implicated in cell proliferation processes
[33,34]. However, the addition of radioactive isotopes on
already efficient MAbs can lead to improved therapeutic
results like that obtained with the anti-CD20 antibodies
[35]. RIT remains attractive for solid tumors where the
antibody penetration is limited and where the cross-fire
phenomenon could lead to the destruction of cells which
were not targeted by the radiolabeled MAb [13]. Accord-
ing to all the published or ongoing clinical studies, RIT
could be applied to micrometastases from solid tumors or
solid tumors in the minimal residual disease states
[6,8,14,15]. One potential limitation of intact human
MAbs for RIT could be their long serum half-life, which
could lead to bone marrow suppression. The use of
human MAb fragments for RIT would reduce their serum
half-life, and possibly circumvent this limitation.
Among solid tumors, colorectal cancers represent one of
the main causes of death, and CEA is well known as an
ideal target antigen for RIT of these cancers [12]. Up to
now, only a few human anti-CEA antibodies have been
described. A human MAb directed against the carbohy-
Table 1: VG-IgG2κ and VG-IgM epitope mapping
Tracer MAb
Gold epitope Inhibitor Mab VG-IgG2κ VG-IgM X4
1F 61 a 2< 1
23 5 A 7 < 1 9 3
3 B17 31 <1 13
4 C E 2 5 9 99 58 3
4X 49 88 96 8
51 9 231 1< 1
aResults are expressed as a percentage of inhibition of the binding of radiolabeled tracer MAbs by an excess of the reference MAbs directed against 
the five Gold CEA epitopes.
Presence of J chain in VG-IgM Figure 2
Presence of J chain in VG-IgM. Western blot analysis of 
VG-IgM (lanes 1, 3, 5, and 7) as compared with control IgM 
(lanes 2, 4, 6, and 8). MAbs transferred to a nitrocellulose 
membrane were analyzed for the presence of human µ heavy 
chain, human κ light chain, human λ light chain, and J chain as 
described in Materials and Methods.BMC Cancer 2004, 4:75 http://www.biomedcentral.com/1471-2407/4/75
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drate moiety of CEA was described by Tsukazaki et al [36].
However, it was poorly characterized, and homology
between the carbohydrate moieties of CEA and related
molecules such as NCA would certainly lead to limited
specificity of this anti-CEA MAb. Very recently, Imakiire et
al. described human antibodies generated using the KM-
Mouse [37]. They demonstrated complement- and cell-
dependent cytotoxicity in vitro and presented preliminary
data on tumor growth inhibition using MKN-45 cells
grafted into SCID mice. However, they did not give any
results on the biodistribution of their antibodies in
radiolabeled form nor indications on how they could be
used in RIT. Anti-CEA MAb PR1A3, which exhibits prefer-
ential binding to cell-bound CEA, was recently human-
Binding of MAbs to soluble phase CEA Figure 3
Binding of MAbs to soluble phase CEA. Precipitation of 125I-CEA with MAbs VG-IgG2κ (■ ), VG-IgM (▲ ), and X4 (● ) fol-
lowing incubation in a soluble phase assay.
Table 2: Tumor to non-tumor tissue ratios of antibody concentrations
24 h 72 h
Tissue VG-IgG2κ X4 VG-IgG2κ X4
Liver 8.63 ± 0.30a 10.98 ± 0.35 13.41 ± 0.41 15.80 ± 0.41
Kidneys 9.00 ± 0.30 7.13 ± 0.37 14.14 ± 0.42 10.33 ± 0.43
Lungs 4.23 ± 0.32 5.13 ± 0.36 6.03 ± 0.40 6.74 ± 0.41
Spleen 13.32 ± 0.33 13.48 ± 0.37 16.54 ± 0.42 17.53 ± 0.42
Heart 6.00 ± 0.30 7.34 ± 0.34 8.80 ± 0.41 10.00 ± 0.43
Muscle 28.30 ± 0.31 28.78 ± 0.36 36.48 ± 0.44 36.18 ± 0.45
Bone 31.15 ± 0.64 24.50 ± 0.68 26.14 ± 0.43 23.95 ± 0.42
Skin 5.74 ± 0.29 7.01 ± 0.33 9.10 ± 0.42 10.05 ± 0.43
Stomach 19.13 ± 0.31 12.64 ± 0.38 59.76 ± 0.46 40.04 ± 0.49
Small bowel 23.73 ± 0.30 26.12 ± 0.34 37.84 ± 0.42 41.97 ± 0.43
Large bowel 33.92 ± 0.29 33.57 ± 0.35 67.68 ± 0.42 68.45 ± 0.45
Carcass 10.39 ± 0.30 12.39 ± 0.34 15.39 ± 0.40 17.22 ± 0.42
Blood 1.74 ± 0.32 2.24 ± 0.38 2.81 ± 0.41 3.15 ± 0.42
aRatios were calculated by dividing the %ID/g of the tumor by that obtained in each individual organ.BMC Cancer 2004, 4:75 http://www.biomedcentral.com/1471-2407/4/75
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ized, but to our knowledge, this MAb has not yet been
evaluated in experimental or clinical studies [20]. A few
clinical phase I or II trials suggest a certain degree of effi-
ciency of humanized or chimeric anti-CEA mAbs, radiola-
beled with either 131Iodine or 90Ytrium, in heavily pre-
treated patients with metastatic colorectal cancer (MCRC)
CT84.66 [8,14,15]. One of these trials showed a few
objective tumor responses in MCRC of small-volume dis-
ease and provided some arguments in favor of this kind of
therapy in an adjuvant setting [8]. The development of
such chimeric, humanized, or human anti-CEA MAbs by
different academic groups and industrial companies
underlines the interest to generate a fully human MAb for
RIT of colorectal cancers.
In the present study, the characterization of our fully
human anti-CEA MAbs was conducted in comparison
with the chimerized anti-CEA MAb X4, which has been
shown to be clinically relevant [19,24]. Furthermore, the
newly developed human MAbs were found to be directed
against the same CEA epitope, namely Gold 4 (Table 1).
That makes X4 an even better positive control, in particu-
lar, for the affinity measurements; although no difference
has been reported between the different CEA epitopes for
tumor immunotargeting [26]. VG-IgG2κ and VG-IgM are
CEA-specific, i.e., NCA negative. This is particularly
important for VG-IgM since the avidity generated by the
pentameric molecule could have resulted in enhanced
non-specific binding to CEA-related molecules.
Biodistribution studies in LS174T tumor bearing nude mice Figure 4
Biodistribution studies in LS174T tumor bearing nude mice. Biodistribution study of 125I-VG-IgG2κ (■ ) as compared 
with 131I-X4 (❍ ) in LS174T tumor bearing nude mice dissected 24 and 72 h after i.v. co-injection. The tissues shown are (from 
left to right) tumor, liver, kidneys, lung, spleen, heart, muscle, bone, skin, stomach, low bowel, colon, carcass and blood. Results 
are expressed in terms of %ID/g ± SD.BMC Cancer 2004, 4:75 http://www.biomedcentral.com/1471-2407/4/75
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The VG-IgG2κ and VG-IgM affinity constants were found
to be similar to that of the control MAb X4 when deter-
mined using the BIACORE technology, but the binding of
the human MAbs to soluble CEA (Figure 3) was clearly
weaker than that of X4. This is particularly interesting for
in vivo use in patients where some circulating CEA can be
found. The molecular basis of this observation is not clear.
The only possible comparison is with MAb PR1A3, which
preferentially binds to cell bound CEA, and to a recom-
binant chimeric protein containing only the CEA B3
domain [20,38]. This reduced binding to the whole solu-
ble CEA was attributed by the authors to be due to a con-
formational change supposed to occur when the CEA is
shed into the circulation, resulting in steric blocking of
antibody access to the B3 domain [20].
Using human colon carcinoma bearing nude mice, we
obtained high tumor uptakes with VG-IgG2κ, making this
antibody a good candidate for future clinical studies (Fig-
ure 4). In addition to the comparison with chimeric MAb
X4, we also performed biodistribution studies comparing
VG-IgG2κ and the murine MAb 35A7, with which we
obtained the highest tumor uptakes in tumor bearing
nude mice [39,40]. Seventy-two hours post injection, 125I-
VG-IgG2κ localized in the tumor up to 26.2 ± 1.7% ID/g
as compared with 28.5 ± 2.8% ID/g for 131I-35A7, suggest-
ing a tumor residence time as long as that observed for
MAb 35A7 (data not shown). These results could seem
contradictory, given the fact that the affinity of VG-IgG2κ
for CEA is not as high as that of Mab 35A7. This could be
explained by the "affinity barrier" effect described in solid
tumors by several authors who demonstrated that very
high affinity MAbs localized at the periphery of tumor
nodules and that lower affinity MAbs are able to distribute
homogenously in these nodules [41-43].
Since, up to now, there are no data available on the bio-
distribution of any anti-CEA IgM in mice, we decided to
analyze the biodistribution of our VG-IgM in LS174T
tumor bearing nude mice. The disappointing tumor
uptakes (7.4 ± 2.8 and 1.8 ± 2.4%ID/g tumor at 24 h and
72 h, respectively) could be attributed to a very short half-
life due to poly-Ig receptor expression in the mouse liver
which induces a rapid hepatobiliary transport of poly-IgA
and IgM [44,45]. Based on the results obtained by Bor-
chardt et al., we compared the tumor uptakes following
i.p. and i.v. injection of the VG-IgM [46]. The tumor
uptakes observed after i.p. injection were even lower
(0.25%ID/g tumor at 24 h). These results are in contradic-
tion with those obtained by Borchardt et al. [46]. In SK-
Ov3 peritoneal carcinomatosis bearing nude mice, these
authors showed a marked difference in tumor uptake
between i.v. and i.p. injections of AC6C3-2B12 human
IgM: 39% vs. 0.9%ID/g tumor for i.p. vs. i.v. injection,
respectively, at 24 h and 28% vs. 1.4%ID/g at 48 h [46].
Liver and spleen uptakes were reduced following the i.p.
injection as compared with the i.v. injection, but these
uptakes in normal tissues could be related to this particu-
lar IgM and not relevant for our VG-IgM [46]. Indeed, the
precise nature of the target antigen of their AC6C3-2B12
human IgM is unclear, but the discrepancy between our
respective results could be due to the lack of J chain in
their IgM. Without the J chain, IgM is unable to bind to
the poly-Ig receptor, and as such it is not transported into
the bile nor eliminated rapidly. The presence of the J chain
in our VG-IgM makes it a fully functional IgM but limits
its uptake by the human tumor grafted in nude mice.
Conclusions
In the present study, we described two fully human anti-
CEA MAbs. Even though the results obtained in tumor
bearing nude mice cannot be extrapolated directly to
humans, VG-IgM remains attractive for RIT of CEA-posi-
tive peritoneal carcinomatosis in man [47]since humans
lack hepatic expression of poly-Ig receptor [48]. A first step
toward this aim will be to study the biodistribution and
tumor uptakes of low doses of radiolabeled VG-IgM. VG-
IgG2κ is obviously a candidate for radioimmunotherapy
in intact form, as F(ab')2 fragments, or as a bispecific anti-
body to be used in the affinity enhancement system (AES)
approach [49]. Furthermore, we intend to test it in a
model for immunophotodetection of cancer [50], and it
could be the basis for preparing different anti-CEA immu-
noconjugates [51,52] and fusion proteins [53].
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